Navigation Links
Structures of marine toxins provide insight into their effectiveness as cancer drugs

Vibrantly colored creatures from the depths of the South Pacific Ocean harbor toxins that potentially can act as powerful anti-cancer drugs, according to research findings from University of Wisconsin-Madison biochemists and their Italian colleagues.

The research team has defined the structure of the toxins and provided a basic understanding that can be used to synthesize pharmaceuticals, according to a study published this week in the Proceedings of the National Academy of Sciences (PNAS).

"We've determined how this class of toxins interacts with actin," an important protein responsible for cellular structure and movement, says Ivan Rayment, a professor of biochemistry in the College of Agricultural and Life Sciences who worked with John Allingham, a postdoctoral fellow, on the study. "We're adding to fundamental understanding which will be taken up by others to simplify chemical synthesis of what could potentially be powerful cancer treatments."

The toxins, which are produced naturally by organisms that exist symbiotically on deep-sea sponges, work by disrupting the activity of actin, an abundant protein that gives structure to eukaryotic cells.

"Actin forms long chains, or filaments, that are essential for cellular locomotion, division and growth," explains Allingham. "Because cancer cell masses grow faster than other cells in the body, actin provides an excellent target for drugs that could inhibit such rapid growth."

Adds Allingham: "These marine toxins can knock out the lynchpins in these long chains or cap their ends and kill cancer cells. Moreover, initial work shows that even a low dose of these toxins can bring a significant response."

Prior to the study published in PNAS, it was known that the marine toxins affect several forms of cancer - but not how they worked, says Rayment. The recent findings will enable the toxins to be synthesized in a lab instead of harvested from the depths of the ocean floor, mea ning that the drugs can be engineered to be as effective as possible.

"In order to chemically synthesize a better drug, it is a good idea to know how the natural compound works," he says. "Scientists who study natural products take their cues from what nature has already done. We're adding deep biochemical meaning to this area."

He adds that synthetic chemists hope that actin-based drugs might one day rival the success of Taxol, a powerful drug derived from a natural product that keeps breast-cancer cells from dividing.

"Actin-based drugs have not yet been used as successful drugs as have those that target microtubules, like Taxol, in part because we haven't understood how to target actin," Rayment explains.


'"/>

Source:University of Wisconsin-Madison


Related biology news :

1. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
2. Sequencing of marine bacterium will help study of cell communication
3. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
4. UN environmental agency steps up battle against marine pollution
5. Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils
6. Deep thinking: Scientists sequence a cold-loving marine microbe
7. UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina
8. UF study first to quantify validity of DNA I.D. tool using marine snails
9. Prenatal exposure to marine toxin causes lasting damage
10. Restaurant seafood prices since 1850s help plot marine harvests through history
11. Compound from marine bacteria shows potential as multiple myeloma therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selector™ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology: